Wharton Study Investigates GLP-1 Drugs' Impact on Financial Decision-Making
A growing body of research suggests that GLP-1 drugs, primarily recognized for their role in weight management, may also influence behaviors beyond food, particularly in financial decision-making. Experts at the Wharton School of the University of Pennsylvania are initiating a study to investigate whether these drugs can help individuals curb risky financial behaviors such as gambling and compulsive shopping. Michael Platt, a neuroscientist and professor at Wharton, stated, "We believe GLP-1s will ultimately lead to some structural remodeling of the brain, which is where some of those long-term impacts on food choice could show up, but also on financial decision-making." He further noted that this could potentially be beneficial for the average person, suggesting that it might lead to increased savings. The study aims to explore how GLP-1s affect the body's reward system, which is crucial in reinforcing certain behaviors. If successful, these drugs could assist individuals in resisting temptations related to luxury purchases and gambling, thereby fostering better financial habits. The research is inspired by earlier findings from Geoff Cook, CEO of Noom, who posited that dampening the reward drive might also reduce the appetite for high-risk financial ventures. The Wharton team plans to recruit approximately 180 participants for this study, which is set to commence in mid-October and conclude around March 2027 at the University of Pennsylvania's MindCORE research lab. Participants will undergo a series of assessments, including demographic and mental health questionnaires, alongside cognitive exercises. They will also participate in magnetic resonance imaging (MRI) while engaging in tasks related to both food and financial decisions. The first financial task involves passive viewing of various spending opportunities, allowing researchers to observe spontaneous brain responses without prompting any actions. The second task requires participants to make a financial choice, such as opting for $20 now versus $50 in two months, providing insights into their valuation of immediate versus delayed rewards. This study will measure changes in brain activity and blood flow to understand how GLP-1 usage might alter subjective value perceptions in financial contexts. After the MRI sessions, participants will be required to act on one of their decisions, ensuring the integrity of their choices. This research could pave the way for understanding how GLP-1 drugs might not only assist in weight loss but also in promoting healthier financial behaviors, ultimately contributing to better overall well-being.




